Tags

Type your tag names separated by a space and hit enter

Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Exp Clin Endocrinol Diabetes. 2014 May; 122(5):268-72.EC

Abstract

BACKGROUND

Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumour. A common mutation of papillary thyroid carcinoma (PTC) is the somatic mutation of the BRAF (V600E) gene.

AIM

The aim was to 1) determine the association of lymph node metastases of PTC with the BRAF gene mutation of primary tumour; 2) evaluate association of the BRAF mutation in the -primary tumour with clinicopathological para-meters; 3) examine the extent of genetic heterogeneity by monitoring the BRAF mutation in multicentric tumours.

SUBJECTS AND METHODS

Retrospective analysis of the BRAF (V600E) mutation in PTC and PTC neck lymph node metastases in 156 patients operated from 2003 to 2012 in Prague and Zlín, the Czech Republic, using a qPCR assay. The results were correlated with clinicopathological factors.

RESULTS

DNA was successfully extracted from 137 samples. The BRAF (V600E) mutation was detected in 78 cases (56.9%). The patients with BRAF p.Val600Glu mutation of primary tumour had only non-significantly higher risk of cervical lymph node metastases [OR=2.39 (95%) CI 1.00-5.75, p=0.052]. In the classic papillary variant, the BRAF (V600E) mutation was found significantly more often than in other PTC subtypes (p=0.022). We did not confirm any significant association between the BRAF (V600E) mutation and other clinicopathological findings.

CONCLUSION

Except for the higher prevalence in papillary variant of PTC, BRAF p.Val600Glu mutation was not associated with other prognostic clinicopathological factors of PTC. BRAF mutation cannot be regarded as a reliable marker of node metastases in patients with PTC.

Authors+Show Affiliations

Department of Otolaryngology - Head and Neck Surgery, Na Homolce Hospital, Prague, Czech Republic.Laboratory of Experimental Medicine, the Institute of Molecular and -Translational Medicine of the Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.Department of Surgery, Atlas Hospital, Zlín, Czech Republic.Biopsy and Cytology Laboratory of J.A.Baťa, Zlín, Czech Republic.Laboratory of Experimental Medicine, the Institute of Molecular and -Translational Medicine of the Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.Laboratory of Experimental Medicine, the Institute of Molecular and -Translational Medicine of the Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.Department of Nuclear Medicine and Endocrinology, 2nd Medical Faculty, Charles University, Prague, Czech Republic.Department of Pathology, Na Homolce Hospital, Prague, Czech Republic.Surgery Clinics, 3rd Medical Faculty, Charles University and Faculty Hospital Královské Vinohrady, Prague, Czech Republic.Institute of Pathology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.Institute of Pathology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.Department of Endocrinology, Na Homolce Hospital, Prague, Czech -Republic.The 3rd Department of Medicine - Department of Endocrinology and -Metabolism 1st Faculty of Medicine, Charles University in Prague and -General University Hospital in Prague, Czech Republic.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24839220

Citation

Lukas, J, et al. "Correlation Among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma." Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association, vol. 122, no. 5, 2014, pp. 268-72.
Lukas J, Drabek J, Dudesek B, et al. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma. Exp Clin Endocrinol Diabetes. 2014;122(5):268-72.
Lukas, J., Drabek, J., Dudesek, B., Vazan, P., Stranska, J., Jancik, S., Mackova, M., Syrucek, M., Lukas, D., Duskova, J., Dundr, P., Hintnausova, B., & Jiskra, J. (2014). Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma. Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association, 122(5), 268-72. https://doi.org/10.1055/s-0034-1372624
Lukas J, et al. Correlation Among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma. Exp Clin Endocrinol Diabetes. 2014;122(5):268-72. PubMed PMID: 24839220.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma. AU - Lukas,J, AU - Drabek,J, AU - Dudesek,B, AU - Vazan,P, AU - Stranska,J, AU - Jancik,S, AU - Mackova,M, AU - Syrucek,M, AU - Lukas,D, AU - Duskova,J, AU - Dundr,P, AU - Hintnausova,B, AU - Jiskra,J, Y1 - 2014/05/16/ PY - 2014/5/20/entrez PY - 2014/5/20/pubmed PY - 2014/12/31/medline SP - 268 EP - 72 JF - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association JO - Exp. Clin. Endocrinol. Diabetes VL - 122 IS - 5 N2 - BACKGROUND: Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumour. A common mutation of papillary thyroid carcinoma (PTC) is the somatic mutation of the BRAF (V600E) gene. AIM: The aim was to 1) determine the association of lymph node metastases of PTC with the BRAF gene mutation of primary tumour; 2) evaluate association of the BRAF mutation in the -primary tumour with clinicopathological para-meters; 3) examine the extent of genetic heterogeneity by monitoring the BRAF mutation in multicentric tumours. SUBJECTS AND METHODS: Retrospective analysis of the BRAF (V600E) mutation in PTC and PTC neck lymph node metastases in 156 patients operated from 2003 to 2012 in Prague and Zlín, the Czech Republic, using a qPCR assay. The results were correlated with clinicopathological factors. RESULTS: DNA was successfully extracted from 137 samples. The BRAF (V600E) mutation was detected in 78 cases (56.9%). The patients with BRAF p.Val600Glu mutation of primary tumour had only non-significantly higher risk of cervical lymph node metastases [OR=2.39 (95%) CI 1.00-5.75, p=0.052]. In the classic papillary variant, the BRAF (V600E) mutation was found significantly more often than in other PTC subtypes (p=0.022). We did not confirm any significant association between the BRAF (V600E) mutation and other clinicopathological findings. CONCLUSION: Except for the higher prevalence in papillary variant of PTC, BRAF p.Val600Glu mutation was not associated with other prognostic clinicopathological factors of PTC. BRAF mutation cannot be regarded as a reliable marker of node metastases in patients with PTC. SN - 1439-3646 UR - https://www.unboundmedicine.com/medline/citation/24839220/Correlation_among_the_BRAF_gene_mutation_status_clinicopathological_features_of_primary_tumour_and_lymph_node_metastasizing_of_papillary_thyroid_carcinoma_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0034-1372624 DB - PRIME DP - Unbound Medicine ER -